Encouraging Signs For Arcus In TIGIT Race, But Gilead Holds Fire

Triplet Might Offer Arcus An Edge

Arcus Biosciences has one of the most advanced TIGIT programs, but early data were not strong enough to convince partner Gilead to commit to funding pivotal studies just yet

Arcus Biosciences has presented early Phase II data on its TIGIT inhibitor, domvanalimab, but partner Gilead Sciences, Inc. is not yet committing to funding pivotal studies, even as an interim analyses, particularly of a triplet combination, give encouraging hints of efficacy.

TIGIT inhibitors are a promising new avenue in immuno-oncology therapy, and Arcus is in the race to bring the first...